Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CELEXA vs LUVOX CR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by blocking reuptake of serotonin into presynaptic neurons.
Selective serotonin reuptake inhibitor (SSRI); increases serotonin availability in the synaptic cleft by blocking serotonin reuptake transporters (SERT).
Major depressive disorder,Obsessive-compulsive disorder,Panic disorder,Social anxiety disorder,Generalized anxiety disorder,Post-traumatic stress disorder,Premenstrual dysphoric disorder
Obsessive-compulsive disorder (OCD),Social anxiety disorder,Panic disorder,Post-traumatic stress disorder,Premenstrual dysphoric disorder
20 mg orally once daily initially, may increase to 40 mg once daily after at least 1 week; maximum 40 mg/day.
100-300 mg orally once daily at bedtime
Terminal elimination half-life is approximately 35 hours (range 23–45 h) in healthy adults. This long half-life allows once-daily dosing; steady state is reached in about 1 week. In elderly patients, half-life may extend to 45–90 hours.
The terminal elimination half-life is approximately 15-20 hours after single doses and 17-26 hours after multiple doses. This supports once-daily dosing, with steady-state achieved within 1-2 weeks.
Hepatic via CYP2C19 (major), CYP3A4, and CYP2D6; active metabolites: S-demethylcitalopram and didemethylcitalopram.
Primarily hepatic via CYP2D6; undergoes extensive first-pass metabolism; major metabolites are glucuronide conjugates.
Primarily renal: 75% as metabolites (10% as parent citalopram, 65% as desmethylcitalopram, didesmethylcitalopram, and citalopram-N-oxide). Fecal excretion accounts for approximately 20% of the dose. Biliary excretion minimal.
Approximately 94% of a dose is excreted in urine, with less than 4% as unchanged drug. The remainder is eliminated in feces. Renal excretion of metabolites accounts for the majority of elimination.
Approximately 80% bound to plasma proteins (primarily albumin and α1-acid glycoprotein). Binding is independent of drug concentration.
Approximately 80% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Mean Vd is 12 L/kg (range 8–16 L/kg). This large Vd indicates extensive extravascular distribution, including CNS penetration. High Vd contributes to the long half-life.
The apparent volume of distribution is approximately 5-9 L/kg, indicating extensive tissue distribution beyond plasma volume.
Oral bioavailability is approximately 80% (range 60–90%). No significant first-pass metabolism. Food does not affect bioavailability.
Oral bioavailability is approximately 50-70% due to first-pass metabolism. Administration with food may slightly delay absorption but does not significantly alter the extent of absorption.
GFR >20 m L/min: no adjustment; GFR ≤20 m L/min: maximum 20 mg/day; not recommended for GFR <10 m L/min.
No specific dose adjustment required; use caution in severe renal impairment (Cr Cl < 30 m L/min) and consider lower starting dose.
Child-Pugh Class A: 10 mg once daily; Child-Pugh Class B or C: maximum 20 mg/day with careful titration.
Child-Pugh Class A: 50 mg/day; Class B: 25 mg/day; Class C: not recommended.
Adolescents 12-17 years: 10 mg orally once daily initially, may increase to 20 mg once daily after 3 weeks; maximum 20 mg/day. Children <12 years: not approved.
Not approved for patients under 18 years.
Patients >60 years: 10 mg orally once daily initially, maximum 20 mg once daily.
Initiate at 50 mg/day; titrate slowly to a maximum of 150 mg/day.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
QT prolongation, serotonin syndrome, hyponatremia, increased risk of bleeding, activation of mania/hypomania, seizures, angle-closure glaucoma, sexual dysfunction, and discontinuation syndrome.
Serotonin syndrome,Risk of bleeding with NSAIDs/aspirin,Activation of mania/hypomania,Seizure risk,Angle-closure glaucoma risk,Sexual dysfunction,Withdrawal symptoms on discontinuation
Concomitant use with MAOIs or within 14 days of MAOI use, concomitant use with pimozide, hypersensitivity to citalopram or any excipients.
Concomitant use with MAOIs or within 14 days of MAOI discontinuation,Concomitant use with pimozide or thioridazine,Known hypersensitivity to fluvoxamine
No specific food interactions. Avoid grapefruit and grapefruit juice as they may increase citalopram levels via CYP3A4 inhibition. Alcohol may exacerbate CNS depression and should be avoided.
No specific dietary restrictions. Grapefruit and grapefruit juice may increase fluvoxamine levels; avoid large quantities. Limit caffeine intake, as fluvoxamine may decrease caffeine clearance and increase stimulant effects.
First trimester: Data insufficient to definitively assess major malformation risk; some studies suggest small increased risk of cardiac defects (e.g., septal defects). Second/Third trimester: Risk of persistent pulmonary hypertension of the newborn (PPHN), preterm birth, low birth weight; late third trimester exposure may cause neonatal adaptation syndrome (irritability, respiratory distress, feeding difficulties).
First trimester: Epidemiologic studies have not consistently demonstrated an increased risk of major congenital anomalies; however, some studies suggest a small increased risk of cardiovascular malformations (e.g., ventricular septal defect) with maternal use of SSRIs overall. Fluvoxamine has limited data but is considered low risk. Second and third trimesters: Late pregnancy exposure may be associated with persistent pulmonary hypertension of the newborn (PPHN) (absolute risk about 1-2 per 1000), preterm birth, and transient neonatal adaptation syndrome (irritability, tachypnea, poor feeding) requiring monitoring. Neonatal withdrawal syndrome (serotonin discontinuation syndrome) may occur.
Citalopram is excreted into breast milk; average infant dose relative to maternal weight-adjusted dose is 3.9% (range 1.7-8.5%). Milk-to-plasma ratio (M/P) approximately 1.5. Cases of adverse effects in breastfed infants (excessive somnolence, poor feeding) reported; caution with higher maternal doses. Benefits of breastfeeding generally outweigh risks for mild cases, but alternative agents with lower M/P (e.g., sertraline, paroxetine) may be preferred for moderate-severe depression.
Fluvoxamine is excreted into breast milk with an M/P ratio of approximately 0.29. Relative infant dose is estimated at 1.5-2% of maternal weight-adjusted dose. Cases of adverse effects in breastfed infants (e.g., irritability, poor feeding, sedation) are rare. Breastfeeding is generally considered acceptable with monitoring for infant neurobehavioral changes.
Pregnancy may reduce citalopram plasma concentrations by 30-50% due to increased volume of distribution and enhanced hepatic clearance (CYP2C19 induction). Dose adjustment should be guided by clinical response (depressive symptom monitoring) and trough serum concentrations if available. A 30-50% dose increase (e.g., from 20 mg to 30-40 mg) may be needed, especially in third trimester. Postpartum: Dose should be tapered back to pre-pregnancy levels within 1–2 weeks to avoid toxicity.
No routine dose adjustment is required for fluvoxamine during pregnancy. However, due to increased volume of distribution and enhanced hepatic metabolism (CYP1A2, CYP2D6) in pregnancy, some patients may require dose adjustments to maintain efficacy; therapeutic drug monitoring is not standard but consider checking trough levels. Initiate at lowest effective dose and titrate based on clinical response. Postpartum: Reduce dose pre-conception levels if increased during pregnancy to avoid toxicity.
Celexa (citalopram) is an SSRI antidepressant. Key pearls: (1) Max dose 40 mg/day due to QT prolongation risk at higher doses; (2) CYP2C19 and CYP3A4 metabolism; avoid with MAOIs and linezolid; (3) Onset of therapeutic effect takes 2-4 weeks; (4) More selective for serotonin reuptake than fluoxetine or paroxetine, with fewer drug interactions; (5) May cause mild SIADH in elderly; (6) Abrupt discontinuation can cause withdrawal syndrome; (7) Electrolyte monitoring recommended in patients at risk for QT prolongation.
LUVOX CR is an extended-release formulation of fluvoxamine, an SSRI approved for OCD. Dosing: start 100 mg at bedtime, titrate by 50 mg weekly up to 300 mg. Avoid abrupt discontinuation due to withdrawal symptoms. Monitor for serotonin syndrome, especially with concomitant serotonergic drugs. CR tablets must be swallowed whole; do not crush or chew.
Take exactly as prescribed; do not increase dose without consulting your doctor.,It may take 2-4 weeks to feel the full benefit; do not stop abruptly.,Avoid alcohol while taking this medication.,Report any symptoms of serotonin syndrome (agitation, hallucinations, rapid heart rate, fever, muscle stiffness) immediately.,Notify your doctor if you experience unusual bleeding or bruising, or if you have a history of QT prolongation or electrolyte disturbances.
Take LUVOX CR once daily at bedtime to minimize daytime sedation.,Swallow the tablet whole; do not crush, chew, or cut it.,May take 2-4 weeks for therapeutic effect; consistent adherence is important.,Do not stop taking abruptly; consult your doctor before discontinuing.,Avoid alcohol, as it may increase drowsiness and risk of adverse effects.,Report any suicidal thoughts, unusual mood changes, or serotonin syndrome symptoms (e.g., agitation, hallucinations, fever, rapid heart rate).,Use caution when driving or operating machinery until you know how LUVOX affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CELEXA vs LUVOX CR, answered by our medical review team.
CELEXA is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by blocking reuptake of serotonin into presynaptic neurons.. LUVOX CR is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); increases serotonin availability in the synaptic cleft by blocking serotonin reuptake transporters (SERT).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CELEXA and LUVOX CR depend on the specific clinical indication. These are both SSRI Antidepressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CELEXA is: 20 mg orally once daily initially, may increase to 40 mg once daily after at least 1 week; maximum 40 mg/day.. The standard adult dose of LUVOX CR is: 100-300 mg orally once daily at bedtime. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CELEXA and LUVOX CR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CELEXA is classified as Category C. First trimester: Data insufficient to definitively assess major malformation risk; some studies suggest small increased risk of cardiac defects (e.g., septal defects). Second/Third. LUVOX CR is classified as Category C. First trimester: Epidemiologic studies have not consistently demonstrated an increased risk of major congenital anomalies; however, some studies suggest a small increased risk of c. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.